CL2015001702A1 - Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c. - Google Patents

Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.

Info

Publication number: CL2015001702A1
Authority: CL; Chile
Prior art keywords: tricyclic; hepatitis; treatment; pharmaceutical composition; antiviral compounds
Prior art date: 2012-12-21

Application number

CL2015001702A

Other languages

English (en)

Inventor

John O Link

Jeromy J Cottell

Elizabeth M Bacon

Teresa Alejandra Trejo-Martin

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-21

Filing date

2015-06-17

Publication date

2015-08-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50974893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001702(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-06-17 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2015-08-07 Publication of CL2015001702A1 publication Critical patent/CL2015001702A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CL2015001702A 2012-12-21 2015-06-17 Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c. CL2015001702A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261745452P	2012-12-21	2012-12-21
US13/830,346 US9233974B2 (en)	2012-12-21	2013-03-14	Antiviral compounds

Publications (1)

Publication Number	Publication Date
CL2015001702A1 true CL2015001702A1 (es)	2015-08-07

Family

ID=50974893

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2015001702A CL2015001702A1 (es)	2012-12-21	2015-06-17	Compuestos triciclicos antivirales; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.

Country Status (28)

Country	Link
US (5)	US9233974B2 (es)
EP (3)	EP3239152A1 (es)
JP (1)	JP6333849B2 (es)
KR (2)	KR20200118903A (es)
CN (2)	CN107011350A (es)
AP (1)	AP2015008511A0 (es)
AR (1)	AR094262A1 (es)
AU (1)	AU2013361195B2 (es)
BR (1)	BR112015014333A8 (es)
CA (1)	CA2893963C (es)
CL (1)	CL2015001702A1 (es)
CR (1)	CR20150370A (es)
EA (2)	EA201790781A3 (es)
ES (1)	ES2626392T3 (es)
HK (2)	HK1214594A1 (es)
IL (1)	IL239496A0 (es)
MA (1)	MA38261A1 (es)
MD (1)	MD20150062A2 (es)
MX (1)	MX2015007888A (es)
PE (1)	PE20151423A1 (es)
PH (1)	PH12015501354A1 (es)
PL (1)	PL2935279T3 (es)
PT (1)	PT2935279T (es)
SG (1)	SG11201504746PA (es)
SI (1)	SI2935279T1 (es)
TW (2)	TWI613202B (es)
UY (1)	UY35241A (es)
WO (1)	WO2014100500A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11485753B2 (en)	2012-12-21	2022-11-01	Janssen Pharmaceutica Nv	Substituted nucleosides, nucleotides and analogs thereof

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012068234A2 (en)	2010-11-17	2012-05-24	Gilead Sciences, Inc.	Antiviral compounds
PT2907816T (pt)	2011-11-16	2018-10-18	Gilead Pharmasset Llc	Imidazolilimidazóis condensados como compostos antivirais
US20130309196A1 (en) *	2012-05-16	2013-11-21	Gilead Sciences, Inc.	Antiviral compounds
UA111305C2 (uk)	2012-12-21	2016-04-11	Пфайзер Інк.	Конденсовані лактами арилу та гетероарилу
US9398640B2 (en)	2012-12-21	2016-07-19	Halliburton Energy Services, Inc.	Digital multi-use thermo-cup
TWI627174B (zh)	2013-03-14	2018-06-21	比利時商健生藥品公司	Ｐ２ｘ７調控劑
US9040534B2 (en)	2013-03-14	2015-05-26	Janssen Pharmaceutica Nv	[1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
EP2970271B1 (en)	2013-03-14	2017-11-08	Janssen Pharmaceutica NV	P2x7 modulators
AU2014230814B2 (en)	2013-03-14	2017-12-21	Boehringer Ingelheim International Gmbh	Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
TWI599567B (zh)	2013-03-14	2017-09-21	健生藥品公司	Ｐ２ｘ７調節劑
US9717712B2 (en)	2013-07-02	2017-08-01	Bristol-Myers Squibb Company	Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CN105530933B (zh)	2013-07-17	2018-12-11	百时美施贵宝公司	用于治疗hcv的包含联苯衍生物的组合产品
JP2016529293A (ja)	2013-08-27	2016-09-23	ギリアドファーマセットエルエルシー	２つの抗ウイルス化合物の組合せ製剤
TWI721947B (zh)	2014-06-11	2021-03-21	美商基利法瑪席特有限責任公司	抗病毒化合物的固態形式
AP2016009605A0 (en)	2014-06-17	2016-12-31	Pfizer	Substituted dihydroisoquinolinone compounds
WO2016039977A1 (en)	2014-09-12	2016-03-17	Janssen Pharmaceutica Nv	P2x7 modulators
JP6625616B2 (ja)	2014-09-12	2019-12-25	ヤンセンファーマシューティカエヌ．ベー．	Ｐ２ｘ７調節ｎ−アシル−トリアゾロピラジン
UA118610C2 (uk)	2014-09-12	2019-02-11	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Спіроциклічні інгібітори катепсину c
IL296496B2 (en)	2014-12-26	2024-10-01	Univ Emory	N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN110372559A (zh) *	2014-12-29	2019-10-25	重庆博腾制药科技股份有限公司	一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法
WO2017023631A1 (en)	2015-08-06	2017-02-09	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
CN105732765B (zh) *	2016-02-01	2019-07-26	杭州科巢生物科技有限公司	丙肝药物维帕他韦的新合成方法
CN106916134B (zh) *	2016-04-14	2020-04-17	苏州楚凯药业有限公司	一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法
EP3455219A4 (en)	2016-05-10	2019-12-18	C4 Therapeutics, Inc.	AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562107A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的杂环降解决定子体
EP4483875A3 (en)	2016-05-10	2025-04-02	C4 Therapeutics, Inc.	Spirocyclic degronimers for target protein degradation
CN109641874A (zh)	2016-05-10	2019-04-16	C4医药公司	用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
MX2018014377A (es)	2016-05-27	2019-03-14	Gilead Sciences Inc	Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
CN106831737B (zh) *	2017-02-27	2020-03-17	上海众强药业有限公司	维帕他韦及其衍生物的制备
EP3641762B1 (en)	2017-06-20	2026-02-18	C4 Therapeutics, Inc.	N/o-linked degrons and degronimers for protein degradation
AU2018335411B2 (en) *	2017-09-21	2024-06-27	Riboscience Llc	4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
KR102626210B1 (ko)	2017-12-07	2024-01-18	에모리 유니버시티	N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
TW202035409A (zh)	2018-09-28	2020-10-01	比利時商健生藥品公司	單醯基甘油脂肪酶調節劑
MY205440A (en)	2018-09-28	2024-10-21	Janssen Pharmaceutica Nv	Monoacylglycerol lipase modulators
AU2020358948A1 (en)	2019-09-30	2022-05-26	Janssen Pharmaceutica Nv	Radiolabelled MGL PET ligands
BR112022019077A2 (pt)	2020-03-26	2022-12-27	Janssen Pharmaceutica Nv	Moduladores da monoacilglicerol lipase
CA3219397A1 (en)	2021-05-21	2022-11-24	Gilead Sciences, Inc.	Tetracyclic compounds for the treatment of zika virus infection
JP7725617B2 (ja) *	2021-05-21	2025-08-19	ギリアードサイエンシーズ，インコーポレイテッド	ジカウイルス阻害剤としての五環式誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816570A (en)	1982-11-30	1989-03-28	The Board Of Regents Of The University Of Texas System	Biologically reversible phosphate and phosphonate protective groups
US4968788A (en)	1986-04-04	1990-11-06	Board Of Regents, The University Of Texas System	Biologically reversible phosphate and phosphonate protective gruops
EP0481214B1 (en)	1990-09-14	1998-06-24	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Prodrugs of phosphonates
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
DK1778702T3 (da)	2004-07-16	2011-10-17	Gilead Sciences Inc	Antivirale forbindelser
US7741347B2 (en) *	2007-05-17	2010-06-22	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2010096777A1 (en) *	2009-02-23	2010-08-26	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
WO2012068234A2 (en)	2010-11-17	2012-05-24	Gilead Sciences, Inc.	Antiviral compounds
US8552047B2 (en) *	2011-02-07	2013-10-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
US20130309196A1 (en) *	2012-05-16	2013-11-21	Gilead Sciences, Inc.	Antiviral compounds
AR091279A1 (es)	2012-06-08	2015-01-21	Gilead Sciences Inc	Inhibidores macrociclicos de virus flaviviridae

2013
- 2013-03-14 US US13/830,346 patent/US9233974B2/en active Active
- 2013-12-19 CN CN201710186037.1A patent/CN107011350A/zh active Pending
- 2013-12-19 EP EP17160687.4A patent/EP3239152A1/en not_active Withdrawn
- 2013-12-19 ES ES13819144.0T patent/ES2626392T3/es active Active
- 2013-12-19 AU AU2013361195A patent/AU2013361195B2/en active Active
- 2013-12-19 PE PE2015001025A patent/PE20151423A1/es not_active Application Discontinuation
- 2013-12-19 SG SG11201504746PA patent/SG11201504746PA/en unknown
- 2013-12-19 EP EP18169933.1A patent/EP3404030A1/en not_active Withdrawn
- 2013-12-19 CA CA2893963A patent/CA2893963C/en active Active
- 2013-12-19 PT PT138191440T patent/PT2935279T/pt unknown
- 2013-12-19 PL PL13819144T patent/PL2935279T3/pl unknown
- 2013-12-19 EA EA201790781A patent/EA201790781A3/ru unknown
- 2013-12-19 EP EP13819144.0A patent/EP2935279B1/en active Active
- 2013-12-19 KR KR1020207028460A patent/KR20200118903A/ko not_active Ceased
- 2013-12-19 CN CN201380066203.4A patent/CN104918943B/zh active Active
- 2013-12-19 AP AP2015008511A patent/AP2015008511A0/xx unknown
- 2013-12-19 KR KR1020157018764A patent/KR102164390B1/ko active Active
- 2013-12-19 SI SI201330634A patent/SI2935279T1/sl unknown
- 2013-12-19 MA MA38261A patent/MA38261A1/fr unknown
- 2013-12-19 EA EA201590868A patent/EA027828B1/ru not_active IP Right Cessation
- 2013-12-19 MD MDA20150062A patent/MD20150062A2/ro not_active Application Discontinuation
- 2013-12-19 WO PCT/US2013/076734 patent/WO2014100500A1/en not_active Ceased
- 2013-12-19 BR BR112015014333A patent/BR112015014333A8/pt not_active Application Discontinuation
- 2013-12-19 JP JP2015549743A patent/JP6333849B2/ja active Active
- 2013-12-19 MX MX2015007888A patent/MX2015007888A/es unknown
- 2013-12-19 HK HK16102505.6A patent/HK1214594A1/zh unknown
- 2013-12-20 TW TW102147531A patent/TWI613202B/zh active
- 2013-12-20 UY UY0001035241A patent/UY35241A/es not_active Application Discontinuation
- 2013-12-20 AR ARP130105004A patent/AR094262A1/es unknown
- 2013-12-20 TW TW106146566A patent/TW201835087A/zh unknown
2015
- 2015-06-15 PH PH12015501354A patent/PH12015501354A1/en unknown
- 2015-06-17 CL CL2015001702A patent/CL2015001702A1/es unknown
- 2015-06-18 IL IL239496A patent/IL239496A0/en unknown
- 2015-07-10 CR CR20150370A patent/CR20150370A/es unknown
- 2015-12-03 US US14/957,988 patent/US20160083395A1/en not_active Abandoned
2016
- 2016-08-24 US US15/246,074 patent/US20160362416A1/en not_active Abandoned
2017
- 2017-08-16 US US15/679,014 patent/US20170369502A1/en not_active Abandoned
2018
- 2018-01-22 US US15/876,909 patent/US20180244684A1/en not_active Abandoned
- 2018-04-10 HK HK18104658.5A patent/HK1245263A1/en unknown

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11485753B2 (en)	2012-12-21	2022-11-01	Janssen Pharmaceutica Nv	Substituted nucleosides, nucleotides and analogs thereof
US12173025B2 (en)	2012-12-21	2024-12-24	Janssen Pharmaceuticals, Inc.	Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number	Publication date
US20160083395A1 (en)	2016-03-24
WO2014100500A1 (en)	2014-06-26
CN107011350A (zh)	2017-08-04
TWI613202B (zh)	2018-02-01
KR20150100728A (ko)	2015-09-02
BR112015014333A2 (pt)	2017-07-11
CR20150370A (es)	2015-08-14
CA2893963C (en)	2021-09-07
MD20150062A2 (ro)	2015-12-31
SI2935279T1 (sl)	2017-06-30
PE20151423A1 (es)	2015-10-17
CA2893963A1 (en)	2014-06-26
SG11201504746PA (en)	2015-07-30
US20140178336A1 (en)	2014-06-26
US9233974B2 (en)	2016-01-12
AR094262A1 (es)	2015-07-22
KR102164390B1 (ko)	2020-10-12
MX2015007888A (es)	2015-09-29
CN104918943B (zh)	2017-04-05
AP2015008511A0 (en)	2015-06-30
US20160362416A1 (en)	2016-12-15
US20180244684A1 (en)	2018-08-30
ES2626392T3 (es)	2017-07-24
TW201835087A (zh)	2018-10-01
KR20200118903A (ko)	2020-10-16
PL2935279T3 (pl)	2017-08-31
EA201790781A3 (ru)	2017-11-30
EA027828B1 (ru)	2017-09-29
EP2935279B1 (en)	2017-03-15
HK1245263A1 (en)	2018-08-24
EA201590868A1 (ru)	2015-11-30
AU2013361195A1 (en)	2015-06-11
JP6333849B2 (ja)	2018-05-30
PT2935279T (pt)	2017-06-02
HK1216177A1 (en)	2016-10-21
EP3404030A1 (en)	2018-11-21
AU2013361195B2 (en)	2018-05-17
EP3239152A1 (en)	2017-11-01
PH12015501354A1 (en)	2015-09-07
HK1214594A1 (zh)	2016-07-29
JP2016503800A (ja)	2016-02-08
TW201441229A (zh)	2014-11-01
MA38261A1 (fr)	2017-06-30
BR112015014333A8 (pt)	2019-10-15
EP2935279A1 (en)	2015-10-28
EA201790781A2 (ru)	2017-08-31
US20170369502A1 (en)	2017-12-28
IL239496A0 (en)	2015-08-31
CN104918943A (zh)	2015-09-16
UY35241A (es)	2014-07-31

Publication	Publication Date	Title
CL2014002093A1 (es)	2014-11-21	Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2016001509A1 (es)	2016-12-02	Formas cristalinas de los análogos de sofosbuvir antivirales
CL2016000153A1 (es)	2016-07-29	Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2014001829A1 (es)	2015-01-02	Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2013003019A1 (es)	2014-02-14	Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2014003444A1 (es)	2015-10-23	Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
CL2014002557A1 (es)	2014-12-19	Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras.
CL2014001858A1 (es)	2014-09-26	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2015001342A1 (es)	2015-10-02	Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
SI2935303T1 (sl)	2021-08-31	4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV
CL2015000784A1 (es)	2015-06-12	Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
CR20150380A (es)	2015-08-21	Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CL2015000295A1 (es)	2015-04-24	Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2013002939A1 (es)	2014-07-04	Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CL2015001731A1 (es)	2015-08-28	Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
CO6950473A2 (es)	2014-05-20	Novedosos derivados de purina y su uso en el tratamiento de enfermedades
CL2014002726A1 (es)	2015-02-13	Compuestos derivados de pirrolopirimidina y purina; composicion farmaceutica; utiles en el tratamiento del cancer (div. sol. 566-14).
CL2013001891A1 (es)	2014-09-05	Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad.
CL2015001202A1 (es)	2015-07-03	Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2013000016A1 (es)	2013-04-19	Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2013001754A1 (es)	2013-11-29	Compuestos derivados de enonas triciclicas y tetraciclicas de pirazolilo y pirimidinilo; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias.
HUE037347T2 (hu)	2018-08-28	Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
CL2015003444A1 (es)	2016-07-15	Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
CL2014001865A1 (es)	2015-06-26	Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
HUE036387T2 (hu)	2018-07-30	Pirrolopirimidin származékok vírusfertõzések kezelésében való felhasználásra